The side effects of a drug can often be traced to its interactions with proteins other than its intended target. Michael Fitzgerald, an associate professor at Duke University, and his colleagues developed a method for getting a proteome-wide look at what proteins a drug interacts with. By coupling a ligand-binding assay to mass spectrometry, their proof-of-principle study, published online in PNAS in May, was able to show to which proteins the immunosuppressant drug cyclosporin A binds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.